FLJ30679: A Potential Drug Target and Biomarker (G146512)

Target Name: FLJ30679

NCBI ID: G146512

FLJ30679

Other Name(s): uncharacterized protein FLJ30679 | Uncharacterized protein FLJ30679

FLJ30679: A Potential Drug Target and Biomarker

FLJ30679 is a protein that has not yet been characterized, but it is currently a focus of research due to its potential as a drug target and biomarker. The protein is identified as a key regulator of the T-cell receptor (TCR), which plays a crucial role in cell signaling and immune responses. FLJ30679 has been shown to be highly expressed in a variety of tissues, including the brain, spleen, and lymphoid organs, and has been associated with various diseases, including autoimmune diseases and cancer.

The protein encoded by FLJ30679 is a single-pass T-cell receptor protein that contains a unique N-terminal region that is highly conserved among different T-cell receptor subtypes. It consists of a transmembrane domain, a cytoplasmic tail, and an N -terminus that contains a putative glycophosphorylation site. The putative N-terminus of FLJ30679 is known to contain a leucine-rich repeat (LRR), which is a common protein structural motif that has been shown to play a role in various cellular processes, including protein-protein interactions and signaling pathways.

FLJ30679 has been shown to regulate the TCR, which is a complex protein that consists of a variable region that includes a transmembrane domain, a cytoplasmic tail, and an N-terminus that contains a coiled-coil region. The TCR is involved in cell signaling and immune responses, and is composed of several subtypes that are characterized by different variable regions. The FLJ30679 protein has been shown to interact with the TCR and regulate its function.

The potential drug target for FLJ30679 is related to the regulation of the immune response and autoimmune diseases. Autoimmune diseases occur when the immune system attacks the body's own tissues, leading to inflammation, pain, and damage. The TCR is involved in regulating the immune response by allowing T cells to recognize and respond to foreign antigens. FLJ30679 has been shown to regulate the TCR and is Therefore, it may be a potential drug target for treating autoimmune diseases.

In addition to its potential as a drug target, FLJ30679 has also been shown to be a potential biomarker for certain diseases. The protein is expressed in various tissues and has been associated with various diseases, including autoimmune diseases and cancer. The expression of FLJ30679 has has been shown to be elevated in individuals with autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, and has been associated with an increased risk of cancer.

In conclusion, FLJ30679 is a protein that has not yet been characterized, but it is currently a focus of research due to its potential as a drug target and biomarker. The FLJ30679 protein is a key regulator of the T-cell receptor and has been shown to interact with the TCR and regulate its function. The potential drug target for FLJ30679 is related to the regulation of the immune response and autoimmune diseases, and the protein has also been shown to be a potential biomarker for these diseases. Further research is needed to fully understand the role of FLJ30679 in cell signaling and immune responses.

Protein Name: Uncharacterized Protein FLJ30679

The "FLJ30679 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FLJ30679 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets